A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases
Recruiting · NCT06136884 · Registry updated 2026-08-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Recruiting | Phase 1 | 2026-08-17 | NCT06136884 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| A2A Pharmaceuticals Inc. | 1 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Hollings Cancer Center - MUSC | Charleston | United States | 1 |
| Karmanos Cancer Institute | Detroit | United States | 153 |
| Mary Crowley Cancer Research | Dallas | United States | 29 |
| NEXT Oncology -Virginia | Fairfax | United States | 2 |
| Oklahoma Univeristy | Oklahoma City | United States | 1 |
| The University of Texas M.D. Anderson Cancer Center | Houston | United States | 18 |